Previous 10 | Next 10 |
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Oslo, 1 7 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation by the company's management team can be followed as a liv...
No safety concerns found in first two dose level cohorts Enables progression to highest dosing level in assessment of Ultimovacs’ second vaccine technology platform Oslo, 3 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage...
Study assesses impact of UV1 in ovarian cancer maintenance care Addresses unmet medical need among BRCA-negative ovarian cancer patients Enrollment of 184 patients to be coordinated through NSGO-CTU and ENGOT Oslo, 15 December 202 1 : Ultimovacs...
Designation covers UV1 in M etas ta tic M elanoma as sole agent or part of combination S even-year market exclusivity after regulatory approval , if received Oslo, 2 December 202 1 : Ultimovacs ASA ("Ultim...
Oslo, 11 November 202 1 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2021 results today. The presentation by the company's management team will take place at Oslo Cancer Clu...
UV1 vaccine combined with ipilimumab induced immune responses in 91% of melanoma patients Immune responses persist and are detectable up to 5 years Oslo, November 9, 202 1 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage leader in immune stimulato...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR D...
Fifth Phase II trial of UV1 in cancer, and largest disease category to date UV1 will be investigated in combination with the standard-of-care pembrolizumab Expected data read-out by end of 2024 OSLO, Norway, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (...
News, Short Squeeze, Breakout and More Instantly...
The Ultimate Software Group Inc. Company Name:
ULTI Stock Symbol:
NASDAQ Market:
Full recruitment of 154 patients with malignant melanoma in U.S. and Europe in 24 months Study provides randomized data on impact of UV1 on standard-of-care immunotherapy Topline progression-free survival data expected H1 2023 Oslo, 30 June 202 2 : ...
Oslo, 21. March 2022 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced that it will host a key opinion leader (KOL) webinar on the unmet need and treatment landscape of melanoma on Monday, March 28, 2...
Oslo, 1 7 February 202 2 : Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its fourth quarter 2021 results today. The presentation by the company's management team can be followed as a liv...